
- /
- Supported exchanges
- / DU
- / MYD.DU
MYRIAD GENETICS - Dusseldorf Stock Exchang (MYD DU) stock market data APIs
MYRIAD GENETICS - Dusseldorf Stock Exchang Financial Data Overview
There is no Profile data available for MYD.DU.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Or get access to advanced financial data starting only $19.99
Get MYRIAD GENETICS - Dusseldorf Stock Exchang data using free add-ons & libraries
Get MYRIAD GENETICS - Dusseldorf Stock Exchang Fundamental Data
MYRIAD GENETICS - Dusseldorf Stock Exchang Fundamental data includes:
- Net Revenue:
- EBITDA:
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
End-of-day & Earnings data
Get MYRIAD GENETICS - Dusseldorf Stock Exchang Earnings data
What’s included:
- Latest Release: NaN
- EPS/Forecast: NaN
Get MYRIAD GENETICS - Dusseldorf Stock Exchang End-of-day data
EOD Historical Data package for
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
MYRIAD GENETICS - Dusseldorf Stock Exchang News

MYGN Stock Might Rise on Collaboration With CancerCARE
Myriad Genetics, Inc. MYGN recently announced an agreement to enhance education and access to hereditary cancer testing for CancerCARE for Life members. Under the agreement, more than 1 million indiv...


Myriad Genetics Announces Two New Patents Granted for its Molecular Residual Disease (MRD) Assay
Myriad Genetics, Inc. SALT LAKE CITY, Feb. 05, 2025 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic and tumor genomic testing and precision medicine, announced that the ...

Myriad Genetics and Lumea Collaborate to Enhance Access to the Prolaris Biomarker and MyRisk Hereditary Cancer Tests through BxLink Integration
Myriad Genetics, Inc. SALT LAKE CITY, Feb. 05, 2025 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic and genomic tumor testing and precision medicine, and Lumea Inc., a l...

Myriad Genetics Unveils Groundbreaking Eight Weeks’ Gestation NIPT Study Results at Society for Maternal-Fetal Medicine Conference
Myriad Genetics, Inc. Opening plenary session features latest fetal fraction amplification research SALT LAKE CITY, Jan. 29, 2025 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader i...
Or get access to advanced financial data starting only $19.99
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.